Among its objectives are to promote the clinical development of specific therapeutic strategies for tumours associated with hereditary genetic alterations, and to identify the mechanisms of resistance to treatments for breast cancer associated with the BRCA gene. They evaluate new treatment combinations for xenografts derived from tumours in patients associated with the BRCA gene that have progressed to PARP inhibitors.

Through the application of new generation sequencing (NGS), they seek to identify new genes involved in hereditary cancer. With a more global vision, they help to evaluate the physiological impact of multiple genetic analysis of hereditary cancer in the Spanish population.

Visit the research group’s page


Subscribe to our newsletters and be a part of Campus Life

Select the newsletter you want to receive:

By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Hospital Universitari Vall d'Hebron - Institut Català de la Salut.
Purpose: Manage the user’s contact information.
Legitimisation: Express acceptance of the privacy policy.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.